Head and Neck cancer - Pipeline Insight, 2022

Head and Neck cancer - Pipeline Insight, 2022

DelveInsight’s, “Head and Neck cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Head and Neck cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Head and Neck cancer Understanding

Head and Neck cancer: Overview

Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). Most HNSCCA begins in the layer of flat cells (the epithelium) which line the structures of the upper aerodigestive tract, including the mouth, throat, and voice box. HNSCCA accounts for about three to five percent of all cancers in the United States, where, in 2021, an estimated 54,000 people will be diagnosed with head and neck cancer and approximately 11,000 will die of the disease. Globally, there were an estimated 890,000 cases in 2018 along with 450,000 deaths. The five-year survival rate of patients with head and neck cancer is about 60 percent. Environmental risk factors for head and neck cancers include tobacco use, heavy alcohol consumption, prolonged sun exposure, and certain viruses, including human papilloma virus (HPV) and Epstein-Barr virus (EBV). Treatment for head and neck cancer depends on individual factors, including the exact location of the tumor, stage of the tumor, and a person’s general health. These conventional treatments for head and neck cancer (surgery, radiation, and chemotherapy) may be used alone or in combination, depending on stage and location.

""Head and Neck cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Head and Neck cancer pipeline landscape is provided which includes the disease overview and Head and Neck cancer treatment guidelines. The assessment part of the report embraces, in depth Head and Neck cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Head and Neck cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Head and Neck cancer.

In the coming years, the Head and Neck cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Head and Neck cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Head and Neck cancer treatment market. Several potential therapies for Head and Neck cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Head and Neck cancer market size in the coming years.

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Head and Neck cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Head and Neck cancer Emerging Drugs Chapters

This segment of the Head and Neck cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Head and Neck cancer Emerging Drugs

Monalizumab: Innate Pharma

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies. Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies. Monalizumab is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting simultaneously on innate and adaptive immunity, monalizumab may re-establish a broad anti-tumor response. Currently, it is in Phase III stage of clinical trial evaluation to treat Squamous Cell Carcinoma of the Head and Neck.

Niraparib: GlaxoSmithKline

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2. Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models with homologous recombination deficiency that had either mutated or wild type BRCA1/2.

Xevinapant: Debiopharm

Xevinapant (Debio 1143) is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins). In preclinical studies, xevinapant restores sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms. As the most clinically advanced IAP antagonist, xevinapant has established proof of efficacy in combination with chemoradiotherapy (CRT) in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a clinically significant and sustained clinical benefit compared with CRT alone.

Enoblituzumab: MacroGenics

Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 and has been enhanced using MacroGenics’ Fc Optimization platform. B7-H3 is a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. MacroGenics is collaborating on the development and commercialization of enoblituzumab with I-Mab Biopharma in Greater China. MacroGenics retains full development and commercialization rights in all other territories. Currently, it is in Phase II stage of clinical trial evaluation to treat Head and Neck cancer.

Further product details are provided in the report……..

Head and Neck cancer: Therapeutic Assessment

This segment of the report provides insights about the different Head and Neck cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Head and Neck cancer

There are approx. 150+ key companies which are developing the therapies for Head and Neck cancer. The companies which have their Head and Neck cancer drug candidates in the most advanced stage, i.e. phase III include, Innate Pharma.

Phases

DelveInsight’s report covers around 150+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation

Inhalation/Intravenous/Oral

Intranasal

Intravenous

Intravenous/ Subcutaneous

NA

Oral

Oral/intranasal/subcutaneous

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Antibody

Antisense oligonucleotides

Immunotherapy

Monoclonal antibody

Peptides

Protein

Recombinant protein

Small molecule

Stem Cell

Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Head and Neck cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Head and Neck cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Head and Neck cancer drugs.

Head and Neck cancer Report Insights

Head and Neck cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Head and Neck cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Head and Neck cancer drugs?

How many Head and Neck cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Head and Neck cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Head and Neck cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Head and Neck cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Innate Pharma

GlaxoSmithKline

Debiopharm

MacroGenics

Takeda Oncology

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

PNP Therapeutics, Inc.

IntraGel Therapeutics

Incyte Corporation

Corregene Biotechnology Co., Ltd

TyrNovo Ltd.

BioNTech SE

Adlai Nortye Biopharma Co., Ltd.

Merck KGaA

Aveta Biomics, Inc.

Cellectar Biosciences, Inc.

Nanobiotix

ALX Oncology

Nektar Therapeutics

Ikena Oncology

AstraZeneca

Arcus Biosciences, Inc.

Roche

Vaccinex

Pfizer

Astex Pharmaceuticals, Inc.

Eli Lilly and Company

Bayer HealthCare

Kura Oncology

Cue Biopharma

Shanghai Henlius Biotech

Merus N.V.

NanoCarrier Co., Ltd.

Alkermes, Inc.

Rubius Therapeutics

iTeos Belgium SA

Transgene

Boehringer Ingelheim

Immutep S.A.S.

Compugen Ltd

Galectin Therapeutics

BioAtla, Inc.

Betta Pharmaceuticals Co., Ltd.

Jacobio Pharmaceuticals Co., Ltd.

CytomX Therapeutics

Advaxis, Inc.

Inhibrx, Inc.

Celldex Therapeutics

Carisma Therapeutics Inc

Intensity Therapeutics, Inc.

I-Mab Biopharma

Quadriga Biosciences, Inc.

Checkpoint Therapeutics, Inc.

Wellmarker Bio

Genentech, Inc.

Pionyr Immunotherapeutics Inc.

Cyteir Therapeutics, Inc.

Klus Pharma Inc.

Bicycle Therapeutics

Palleon Pharmaceuticals, Inc.

Rapa Therapeutics

SN BioScience

Memgen, Inc.

Key Products

Monalizumab

Niraparib

Xevinapant

Enoblituzumab

CK-301

QBS10072S

A166

E-602

BT5528

TAK-981

RAPA-201

Mitoxantrone Hydrochloride

MEM-288

TJ004309

SNB-101

INT230-6

CT-0508

WM-S1-030

CDX-1140

PY159

MCLA-129

INBRX-106

Autogene cevumeran

JAB-3068

CAB-ROR2-ADC

ADXS-NEO

CX-2029

Ad/PNP

COM701

Eftilagimod alpha

CYT-0851

GR-MD-02

TG4050

BI 765063

TumoCure

EOS-448

Epacadostat

RTX-321

CUE-101

ALKS 4230

CRTE7A2-01

NC-6004

Tipifarnib

MCLA-129

Zimberelimab

HLX10 Plus HLX07

Tolinapant

BAY1905254

OSI-774

cetuximab

VX15/2503

Palbociclib

Olaparib

NT219

BNT113

Buparlisib

Retifanlimab

Avelumab

APG-157

CLR 131

NBTXR3

Evorpacept

Dostarlimab

NKTR-214

IK-175